Maxcyte Stock Market Value

MXCT Stock  USD 3.55  0.03  0.85%   
MaxCyte's market value is the price at which a share of MaxCyte trades on a public exchange. It measures the collective expectations of MaxCyte investors about its performance. MaxCyte is selling for under 3.55 as of the 29th of November 2024; that is 0.85 percent increase since the beginning of the trading day. The stock's last reported lowest price was 3.46.
With this module, you can estimate the performance of a buy and hold strategy of MaxCyte and determine expected loss or profit from investing in MaxCyte over a given investment horizon. Check out MaxCyte Correlation, MaxCyte Volatility and MaxCyte Alpha and Beta module to complement your research on MaxCyte.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.
Symbol

MaxCyte Price To Book Ratio

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MaxCyte. If investors know MaxCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MaxCyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.34)
Revenue Per Share
0.437
Quarterly Revenue Growth
0.02
Return On Assets
(0.11)
Return On Equity
(0.16)
The market value of MaxCyte is measured differently than its book value, which is the value of MaxCyte that is recorded on the company's balance sheet. Investors also form their own opinion of MaxCyte's value that differs from its market value or its book value, called intrinsic value, which is MaxCyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MaxCyte's market value can be influenced by many factors that don't directly affect MaxCyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between MaxCyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if MaxCyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MaxCyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

MaxCyte 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MaxCyte's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MaxCyte.
0.00
10/30/2024
No Change 0.00  0.0 
In 31 days
11/29/2024
0.00
If you would invest  0.00  in MaxCyte on October 30, 2024 and sell it all today you would earn a total of 0.00 from holding MaxCyte or generate 0.0% return on investment in MaxCyte over 30 days. MaxCyte is related to or competes with Sight Sciences, CVRx, Neuropace, Rapid Micro, CONMED, Orthopediatrics Corp, and SurModics. MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-gene... More

MaxCyte Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MaxCyte's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MaxCyte upside and downside potential and time the market with a certain degree of confidence.

MaxCyte Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for MaxCyte's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MaxCyte's standard deviation. In reality, there are many statistical measures that can use MaxCyte historical prices to predict the future MaxCyte's volatility.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of MaxCyte's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.223.516.80
Details
Intrinsic
Valuation
LowRealHigh
1.855.148.43
Details
8 Analysts
Consensus
LowTargetHigh
9.1010.0011.10
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.11-0.1-0.1
Details

MaxCyte Backtested Returns

MaxCyte has Sharpe Ratio of -0.0558, which conveys that the firm had a -0.0558% return per unit of risk over the last 3 months. MaxCyte exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify MaxCyte's Risk Adjusted Performance of (0.05), mean deviation of 2.47, and Standard Deviation of 3.29 to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.38, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MaxCyte will likely underperform. At this point, MaxCyte has a negative expected return of -0.18%. Please make sure to verify MaxCyte's potential upside, rate of daily change, as well as the relationship between the Rate Of Daily Change and relative strength index , to decide if MaxCyte performance from the past will be repeated at some point in the near future.

Auto-correlation

    
  -0.6  

Good reverse predictability

MaxCyte has good reverse predictability. Overlapping area represents the amount of predictability between MaxCyte time series from 30th of October 2024 to 14th of November 2024 and 14th of November 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MaxCyte price movement. The serial correlation of -0.6 indicates that roughly 60.0% of current MaxCyte price fluctuation can be explain by its past prices.
Correlation Coefficient-0.6
Spearman Rank Test-0.15
Residual Average0.0
Price Variance0.01

MaxCyte lagged returns against current returns

Autocorrelation, which is MaxCyte stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting MaxCyte's stock expected returns. We can calculate the autocorrelation of MaxCyte returns to help us make a trade decision. For example, suppose you find that MaxCyte has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
   Current and Lagged Values   
       Timeline  

MaxCyte regressed lagged prices vs. current prices

Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If MaxCyte stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if MaxCyte stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in MaxCyte stock over time.
   Current vs Lagged Prices   
       Timeline  

MaxCyte Lagged Returns

When evaluating MaxCyte's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of MaxCyte stock have on its future price. MaxCyte autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, MaxCyte autocorrelation shows the relationship between MaxCyte stock current value and its past values and can show if there is a momentum factor associated with investing in MaxCyte.
   Regressed Prices   
       Timeline  

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.